McNeil labeling deferrals
This article was originally published in The Tan Sheet
Executive Summary
Firm receives six-month deferral from OTC labeling compliance date for 10-count vials of two Tylenol SKUs and two-count pouches of Motrin IB, Tylenol and Imodium products. In Dec. 21 letter, FDA says product labeling must comply with "Drug Facts" requirements by Nov. 16. J&J division originally sought eight-month deferral for vials to allow time for new wrap-around labeling. In November, McNeil requested additional six months to implement "booklet style" labeling on five pouch products (1"The Tan Sheet" Dec. 10, 2001, p. 3)...
You may also be interested in...
McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.